Scientists in Asia and Africa are racing to discover hardier crop varieties using gene editing tools. But patent restrictions ...

Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

In October, Editas revealed plans to change course, announcing that it would seek to license out its lead CRISPR medicine for sickle cell disease. That search did not identify a commercial partner, ...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take ...

Researchers from the University of Illinois have reported complementary discoveries that will improve scientists' ...

Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

In-vivo gene editing, which alters genetic material within the patient, could expand the potential of CRISPR-based gene editing, Editas said. The company said it aims to demonstrate proof of concept ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

A new kind of cancer gene therapy can be remotely activated at a specific part of the body. The team developed a version of ...